Introduction {#section1-1534735420935643}
============

Insomnia is generally defined as having difficulties to sleep although the patient has enough opportunity.^[@bibr1-1534735420935643]^ Sleep disturbance and insomnia are concomitantly used terms in insomnia researches,^[@bibr2-1534735420935643]^ but sleep disturbance encompasses a wider range of sleep disorders, including sleep maintenance, and dysfunctions related to sleep.^[@bibr3-1534735420935643]^

On an epidemiologic view, insomnia has 4 definitions: insomnia symptoms, symptoms consequent with daytime function, dissatisfaction of sleep quality, and insomnia diagnosis.^[@bibr4-1534735420935643]^ Insomnia symptoms are mostly selected criteria used to measure research subjects' sleep status.^[@bibr4-1534735420935643]^ The *Diagnostic and Statistical Manual of Mental Disorders, 4th edition* (*DSM-IV*), and the International Classification of Sleep Disorders (ISCD) define the criteria of insomnia.^[@bibr5-1534735420935643]^ A sleep disturbance that occurs more than 3 times weekly for 1 month and related to daytime impairment can be regarded as insomnia diagnosis. About one third of the general population has insomnia symptoms, which is the most common sleep disturbance in people.^[@bibr4-1534735420935643]^ Insomnia exacerbates physical conditions and psychological health, including cardiovascular^[@bibr6-1534735420935643]^ and mental disorders,^[@bibr7-1534735420935643]^ and diabetes,^[@bibr8-1534735420935643]^ leading to extreme reductions in the quality of life (QOL).^[@bibr9-1534735420935643]^

Global studies have shown that the prevalence of insomnia was 10% to 60%^[@bibr10-1534735420935643]^ and sleep disturbance tends to be continued. Chronic insomnia, sustained at least for 1 month, occurred in 31% to 75% of insomnia patients, with more than two thirds of patients suffering from longer than 1 year.^[@bibr11-1534735420935643],[@bibr12-1534735420935643]^ In South Korea, 17% of the population had sleep deprivation more than 3 times a week. In 2012, the total direct treatment costs for sleeping difficulties had increased to 1.81 times the costs in 2008.^[@bibr13-1534735420935643]^

Cancer-related insomnia has a significantly higher prevalence than insomnia in the general population,^[@bibr14-1534735420935643]^ ranging from 17% to 70%.^[@bibr15-1534735420935643],[@bibr16-1534735420935643]^ In an 18-month cohort study in the United States, cancer patients' recurrence rates of insomnia were higher than those of noncancer patients. Furthermore, 20% of cancer patients who had a history of insomnia recurrences have suffered from frequent sleep deprivation relapses.^[@bibr14-1534735420935643]^

Insomnia in cancer is hard to categorize into one type. Cancer-related insomnia is composed of primary disorders, secondary insomnia comorbid with other diseases, and insomnia associated with cancer.^[@bibr17-1534735420935643],[@bibr18-1534735420935643]^ Sleeping difficulties in cancer patients occur before and after cancer therapy, and there are many factors involved. The etiology of insomnia in patients with cancer is complex and involves factors ranging from demographic characteristics to precipitating and perpetuating factors of sleep deprivation.^[@bibr19-1534735420935643][@bibr20-1534735420935643]-[@bibr21-1534735420935643]^ Insomnia, fatigue, pain, and depression, also called the symptom cluster of cancer patients, occur with concurrent multiple symptoms.^[@bibr22-1534735420935643],[@bibr23-1534735420935643]^ However, sleep problems are rarely addressed during cancer treatment.^[@bibr24-1534735420935643]^ In cancer care programs, insomnia is not included, and cancer patients do not typically receive psychological treatments.^[@bibr25-1534735420935643],[@bibr26-1534735420935643]^ Moreover, patients are unaware of their sleep deprivation and regard it as a transient symptom due to the cancer treatment steps.^[@bibr16-1534735420935643],[@bibr25-1534735420935643]^ Insomnia in patients with cancer lowers survival rate,^[@bibr27-1534735420935643]^ impairs daytime function, and aggravates the symptoms that result from cancer treatments, such as chronic fatigue and depression.^[@bibr28-1534735420935643],[@bibr29-1534735420935643]^

Cognitive-behavioral therapy for insomnia (CBT-I) is the first recommendation for cancer patients with insomnia to help relieve sleep deprivation,^[@bibr30-1534735420935643]^ and it is utilized when patients suffer from recurrent insomnia.^[@bibr31-1534735420935643]^ Compared with the pharmacotherapy, adherence rates of CBT-I are reduced and dropout rates were increased according to the systematic reviews of CBT-I.^[@bibr30-1534735420935643],[@bibr32-1534735420935643]^ Long-term adherence to CBT-I is difficult.^[@bibr33-1534735420935643]^ Pharmacotherapy is not the first recommended guideline to treat insomnia, but it is the most easily accessible treatment for cancer patients with insomnia.^[@bibr34-1534735420935643]^ Despite their generalizability, hypnotic drugs are only recommended for acute insomnia that lasts less than 4 weeks.^[@bibr35-1534735420935643]^ In addition, cancer patients are reluctant to use additional hypnotic drugs and antipsychotics because they have already taken chemotherapeutic drugs and received high doses of radiation therapies.^[@bibr36-1534735420935643]^ Complementary and alternative medicine has gradually been utilized to care for cancer-related insomnia, using herbal medicine treatments.

Cheonwangbosimdan, first recorded in Effective Formulae Handed Down for Generations (世醫得效方; Shi Yi De Xiao Fang) in 1337,^[@bibr37-1534735420935643],[@bibr38-1534735420935643]^ is a herbal medicine that has been continuously utilized in Chinese medicine and Korean medicine (KM). It alleviates insomnia, anxiety, and palpitation by furnishing energy and stabilizing patients' mind.^[@bibr39-1534735420935643]^ Cheonwangbosimdan can mitigate primary insomnia and secondary insomnia in patients with hyperthyroidism and menopause without severe side effects.^[@bibr40-1534735420935643][@bibr41-1534735420935643]-[@bibr42-1534735420935643]^ However, there is no previous study that has examined the effectiveness of Cheonwangbosimdan on cancer patients. This is the first study to evaluate the feasibility of using Cheonwangbosimdan to treat cancer-related insomnia through a comparison with CBT-I.

Methods {#section2-1534735420935643}
=======

Study Design {#section3-1534735420935643}
------------

This study was a randomized, parallel-group, controlled pilot trial. After screening, 22 eligible subjects who finished cancer therapies were randomly allocated to the Cheonwangbosimdan group or CBT-I control group in a 1:1 ratio. Although this was an open-label trial due to the nature of the treatment, which the subjects could not be blind to, the assessor and clinical investigators independently performed the study. The study flowchart is listed in [Figure 1](#fig1-1534735420935643){ref-type="fig"}, and timeline of participants is presented in [Figure 2](#fig2-1534735420935643){ref-type="fig"}. This study was approved by the Institutional Review Board of Kyung Hee University Hospital at Gangdong (Approval Number KHNMC OH 2017-04-002-001), and each participant submitted an informed consent.

![Study flow chart.](10.1177_1534735420935643-fig1){#fig1-1534735420935643}

![Insomnia Severity Score difference.](10.1177_1534735420935643-fig2){#fig2-1534735420935643}

Inclusion and Exclusion Criteria {#section4-1534735420935643}
--------------------------------

Cancer patients who visited the institution with insomnia and who met the following criteria were included:

1.  Patients who were older than 19 years (either sex)

2.  Patients who have been diagnosed with a malignant tumor (any type of cancer or tumor nodes metastasis \[TNM\] stage)

3.  Patients who have undergone direct cancer treatment within a month to 5 years

4.  Eastern Cooperative Oncology Group Performance Status (ECOG--PS) score was 2 or below

5.  Patients whose Insomnia Severity Index (ISI) score is at least 8

6.  Patients who have suffered sleep deprivation for more than a month

Patients who met any of the following criteria were excluded:

1.  Patients who had insomnia induced by any type of pain, nausea or vomiting, ascites, pleural effusion, or hydrothorax

2.  Patients who had a history of restless legs syndrome

3.  Patients who had sleep apnea

4.  Shift workers

5.  Patients who had substance use disorders diagnosed by the *DSM-5*

6.  Patients who had any type of psychological disorder

7.  Patients who have experienced any type of seizure

8.  Patients who have taken drugs or health supplements related to insomnia within a week

9.  Patients who have undergone CBT-I within a month

10. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) scores were greater than or equal to 2 times the upper normal limit (UNL)

11. Patients whose creatinine levels were greater than 1.5 times the upper or lower limits of the normal range during screening

12. Patients pregnant at the time of the screening, breastfeeding women, or subjects who plan to be pregnant

13. Patients who did not provide informed consent

14. Patients determined by physicians to be unlikely to undergo treatments, outpatient assessments, or answer the surveys required for the protocol

Randomization and Allocation Concealment {#section5-1534735420935643}
----------------------------------------

A statistician not involved in the trial assessment allocated subjects to an intervention or control group using block randomization. Sealed envelopes contained allocation information in a sequence. Participants who had passed the screening test opened the envelops in order, and they were allocated to a group based on the information in the envelope. The researchers who created the blocks and envelopes were blind to the intervention. The randomization information was not opened without specific reasons. Patients in this trial were nonblinded, as the interventions for the 2 groups are innately different. Pharmacists, clinical investigators, and assessors were blind to each other's tasks to minimize biases that may exaggerate the effect sizes of the interventions and increase the dropout rate of the study.

Interventions {#section6-1534735420935643}
-------------

Subjects who had undergone the screening test received the sleep hygiene guidelines and followed the instructions. Korean version of the "Top Sleep Hygiene Tips" produced by the American Sleep Association was utilized for sleep hygiene guidelines.^[@bibr43-1534735420935643]^ Each participant received individual sleep hygiene guidance focused on the patient's insomnia severity.

Cheonwangbosimdan is a KM herbal formula effective at relieving anxiety, sleep deprivation, and palpitations, and it is approved by the Korea Ministry of Food and Drug and manufactured by the Jung Woo Pharmaceutical Co, Ltd. We selected liquid-type drug for treatment to enhance the acceptance rate of oral administration and convenience of patients. Detailed components are listed in [Table 1](#table1-1534735420935643){ref-type="table"}. Subjects received Cheonwangbosimdan liquid at each visit for 4 weeks. Patients took the liquid once a day between meals. This group underwent a 4-week treatment protocol, written in a sleep diary, and maintained sleep hygiene guidelines. On the final visit (visit 5), the assessor evaluated the participants' final results.

###### 

Cheonwangbosimdan Liquid Composition (20 mL).

![](10.1177_1534735420935643-table1)

  Chinese name   Scientific name              Content (mg)
  -------------- ---------------------------- --------------
  Danggui        *Angelica gigas* root        125
  Tianmendong    *Asparagus tuber*            125
  Huanglian      *Coptis* rhizome             250
  Renshen        Ginseng                      62.5
  Fuling         Hoelen                       62.5
  Jiegeng        *Platycodon* root            62.5
  Yuanzhi        *Polygala* root              62.5
  Shengdihuang   *Rehmannia* root             500
  Danshen        *Salvia miltiorrhiza* root   62.5
  Wuweizi        *Schisandra* fruit           125
  Xuanshen       *Scrophularia* root          62.5
  Baiziren       Thujae semen                 125
  Suanzaoren     *Ziziphus* seed              125

Participants underwent CBT-I once per week for 4 weeks with a therapist who had over 5 years of clinical experience. Each participant took personalized therapy based on his/her insomnia conditions using the following 5 interventions^[@bibr31-1534735420935643]^:

1.  *Sleep hygiene*: advice on general items including environmental, mental, and behavioral factors that induce qualified sleep

2.  *Relaxation*: restricted awareness and relaxing therapies that can reduce muscle tension (meditation, breathing, gradual muscle relaxation, guided imagery)

3.  *Sleep restrictions*: limiting the sleep onset

4.  *Stimulus control*: strengthening the correlation between sleep and bedding, keeping the patients from engaging in activities irrelevant to sleeping while in bed

5.  *Cognitive therapies*: examining the attitudes toward sleep and rectifying negative feelings

### Prohibited Drugs {#section7-1534735420935643}

Psycholeptics (ATC Code N05) and psychotonic agents (ATC Code N06) were prohibited during the clinical trial.

Outcomes {#section8-1534735420935643}
--------

### Primary Clinical Outcomes {#section9-1534735420935643}

The primary clinical outcome was the ISI, a self-reported questionnaire that evaluated the features, severity, and effects of insomnia on QOL, composed of 7 questions.^[@bibr31-1534735420935643]^ The Korean version of the ISI was developed in 2014.^[@bibr44-1534735420935643]^ The ISI is a validated method of assessing primary sleep deprivation and insomnia in cancer patients. An ISI score of 8 was the criteria to diagnose a sleep deficiency with adequate sensitivity and specificity. The recall period of the ISI was 2 weeks, and participants completed the ISI once per week during the 4-week interventions.

### Secondary Clinical Outcomes {#section10-1534735420935643}

1.  1. Insomnia survey questionnaire outcomes (PSQI, ESS, SAS, BFI, EQ-5D-5L)

```{=html}
<!-- -->
```
1.   *a*. *Pittsburgh Sleep Quality Index (PSQI)*: The PSQI is a self-reported survey composed of 19 questions in 7 sections that includes sleep latency, subjective sleep quality, sleep consistency, habit of sleep efficiency, sleep disturbances, use of drugs, and daytime dysfunction. The Korean version of the PSQI was created in 2012.^[@bibr45-1534735420935643]^ Given the 4 weeks of recall for this assessment, the PSQI was to be completed at visits 1 and 5.

2.   *b*. *Epworth Sleepiness Scale (ESS)*: The ESS is a self-reported questionnaire that assesses the probability of falling asleep during specific daily life situations. The Korean version was designed in 2011. This test measures the disability of daily life caused by sleep deprivation. The ESS was completed at visits 1 and 5 during the clinical trial.^[@bibr46-1534735420935643]^

3.   *c*. *Zung Self-Rating Anxiety Scale (SAS)*: SAS is a self-reported questionnaire that measures anxiety levels and is composed of 20 questions. Various anxiety symptoms can be measured from emotional and psychological perspectives. The Korean version was developed in 1996.^[@bibr47-1534735420935643],[@bibr48-1534735420935643]^ Patients completed the SAS during visits 1 and 5 during the trial period.

4.   *d*. *Brief Fatigue Inventory (BFI)*: Sleep disorders and fatigue are intimately correlated with each other. The BFI was developed to measure the severity and influence of fatigue associated with tumors and consists of 9 items. The Korean version was developed in 2005.^[@bibr49-1534735420935643],[@bibr50-1534735420935643]^ The BFI was completed during visits 1 and 5 of the trial period.

5.   *e*. *Euroqol-5 Dimensions-5 Levels (EQ-5D-5L)*: EQ-5D-5L is a survey that assesses the status of 5 topics (movability, self-care, daily practices, pain/discomfort, and anxiety/depression). Participants answered questions in 5 levels and evaluated the utility weight of health-related quality of life (HRQoL). The validated Korean version of the EQ-5D-5L^[@bibr51-1534735420935643]^ was completed during visits 1 and 5 during the trial.

```{=html}
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1.  2. *Eastern Cooperative Oncology Group Performance Status score (ECOG-PS)*: ECOG-PS is a scoring system that measures the effects of daily practices on cancer patients' diseases.^[@bibr52-1534735420935643]^ To minimize confounding factors, patients confined to bed were excluded from the trial. The ECOG-PS score was assessed once during the screening phase.

2.  3. *Sleep patterns tested via Fitbit One (activity tracker device)*: Fitbit One is a wearable device for the general population, and it can be used to track physical activity, sleep, and energy consumption. This device was used to gather observational data on patients' sleep durations. Although polysomnography is primarily recommended to assess sleep, this method is inappropriate for assessing sleep durations in daily life. Although actigraphy has been utilized in clinics, the Fitbit One has a higher accuracy in measuring sleep duration than actigraphy, and it is relatively inexpensive compared with polysomnography.^[@bibr53-1534735420935643]^ The following data collected from the Fitbit One were utilized to assess the quality of sleep and the sleep diary adherence rate, and used as an alternative source of data missing from the sleep diary:

```{=html}
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1.   *a*. *Sleep and wake times*: Comparisons with the sleep diary to assess the compliance rate

2.   *b*.  *Sleep onset*: Hours of sleep

3.   *c*. *Frequency of awakening*: Number of awakenings during sleep per day

4.   *d*. *Actual sleeping time*: Daily actual sleeping times of each participant were recorded and used to primarily judge the quality of sleep

5.   *e*. *Sleep diary and drug administration diaries*: To evaluate the quality of sleep and compare the outcomes from identical factors in the Fitbit One data, the sleeping time, awakening time, sleep onset, reason for sleep deprivation, and feelings of fatigue when waking up were recorded in sleep diaries. The Korean translated versions of the morning records from the Sleep Diary version 6.0 created by the National Sleep Foundation were used. Drug administration diaries were compared with Fitbit One data.

### Safety Assessment Outcomes {#section11-1534735420935643}

Blood tests and the vital signs of patients were collected to observe the safety of the interventions and select eligible patients for clinical trials. The adherence rates for the Cheonwangbosimdan liquid and CBT-I groups were assessed by descriptive statistics.

### Sample Size {#section12-1534735420935643}

The primary outcome of study, ISI, is a continuous outcome used to calculate the required sample size. To confirm clinical differences between groups whose levels were higher than moderate, the mean difference was set to a score of 7 based on prior studies. The noninferiority stage was 50% of the required clinical difference score (ISI score of 3.5). Due to the lack of primary experimental studies assessing Cheonwangbosimdan and cancer patients with insomnia, the standard deviation was set to 3.18, following results of a clinical trial for cancer patients with insomnia that used different interventions from the current study and a study of Cheonwangbosimdan on primary insomnia patients.^[@bibr54-1534735420935643],[@bibr55-1534735420935643]^

Following the equation below, when considering 1-sided tests, 80% power, a 5% significance level, and a 20% dropout rate, 22 participants were required and identically divided into 2 groups:

$$n_{c} = \frac{(1 + \lambda)\sigma^{2}{(Z_{\alpha} + Z_{\beta})}^{2}}{\lambda\left( {\left| \mu_{c} \right. - \left. \mu_{t} \right| - d} \right)^{2}}$$

Statistical Analysis {#section13-1534735420935643}
--------------------

### Hypothesis {#section14-1534735420935643}

1.  *Null hypothesis (H0)*: There is no difference between the effects of Cheonwangbosimdan liquid and CBT-I.

2.  *Alternative hypothesis (H1)*: The effects of Cheonwang-bosimdan liquid are superior to those of CBT-I.

### Analysis Group {#section15-1534735420935643}

The data from all participants were analyzed with a full analysis set using an intention-to-treat method, except for participants who met the following criteria:

1.  Subjects who violated the inclusion/exclusion criteria

2.  *Intervention group*: subjects who did not take the drug

3.  *Control group*: subjects who did not undergo CBT-I

4.  Subjects who did not provide any clinical data after screening

### General Rules of Data Analysis {#section16-1534735420935643}

All statistical analyses in the trial were 2-sided sets, and *P* value was 5%. The continuous data from subjects were depicted by descriptive statistics, such as means and 95% confidence intervals (CIs), and categorical data were described using percentages and frequencies. If the outcomes did not satisfy the normal distribution requirements, Mann-Whitney tests were used. To verify the effectiveness of the intervention and changes in means for each group after the 4-week intervention, linear mixed models for repeated measures (MMRM) were utilized. SAS Version 9.4 (SAS Institute Inc) was used to analyze the data.

Adverse Events (AEs) {#section17-1534735420935643}
--------------------

The clinical investigator assessed AEs for patients at each visit during the study period. Clinical adverse effects were judged based on the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE V4.03) by the National Cancer Institute. The severity of the assessments was categorized into 5 grades.

### AE Evaluations and Information {#section18-1534735420935643}

The clinical investigator assessed AEs during the drug utilization period at each visit. Reported AEs and their relationship with interventions were documented in an "Adverse Events Record Card." The clinical investigator also educated participants on how to self-report AEs and related information. The researcher identified AEs through medical examinations at every visit. When an AE was revealed, the director recorded details of the appearance date; disappearance date; severity; results; actions related to side effects; association with drugs, suspected drugs, or interventions except the interventions in the trial; and whether the treatment for AE was taken or not. Clinical AEs were classified based on the CTCAE V4.03.

Data Handling {#section19-1534735420935643}
-------------

### Access to Data {#section20-1534735420935643}

Following the clinical trial phases, only authorized personnel was able to access the data through a pre-described access process. Any access was reported. Security systems were to be maintained to deny access to data from unauthorized personnel.

### Data Protection and Preservation {#section21-1534735420935643}

Research data and records were separately protected in a secure depository. For the final report, the storage manager kept the research documents for 10 years from the end date of the study. After the trial had finished, the case report form and the original versions of the data collected in the trial were submitted to the research sponsor (Korea Institute of Oriental Medicine) within 1 month and stored separately, per institutional review board regulations.

Results {#section22-1534735420935643}
=======

Twenty-four participants were screened, and 22 subjects were randomized by 1:1 ratio. One participant in the intervention group ceased the trial after visit 2 as the patient waived the informed consent. Another in control group refused to follow the staff's instruction and stopped participating in the trial. Based on full analysis set on intention-to-treat analysis, 20 patients divided into 10 subjects in each group were analyzed. On the baseline, there were no difference between the 2 groups, except for the education level.

Demographic features of the 2 groups are described in [Table 2](#table2-1534735420935643){ref-type="table"}.

###### 

Demographic Baseline Feature of Patients.

![](10.1177_1534735420935643-table2)

  Characteristics                                                                  Treatment group       Control group         *P*
  -------------------------------------------------------------------------------- --------------------- --------------------- -------------------------------------------------------------
  Gender (male/female)                                                             7 (63.6%)/4 (36.4%)   4 (36.4%)/7 (63.6%)   .2008
  Age (year)                                                                       63.0 \[53.0-71.0\]    63.0 \[54.0-67.0\]    .8965
  BMI                                                                                                                          .9999
   Underweight                                                                     1 (9.1%)              0 (0.0%)              
   Normal                                                                          5 (45.5%)             5 (45.5%)             
   Overweight                                                                      3 (27.3%)             4 (36.4%)             
   Obese                                                                           2 (18.2%)             2 (18.2%)             
  Education level                                                                                                              .0460[\*](#table-fn2-1534735420935643){ref-type="table-fn"}
   Middle school                                                                   3 (27.3%)             1 (9.1%)              
   High school                                                                     2 (18.2%)             8 (72.7%)             
   University                                                                      6 (54.5%)             2 (18.2%)             
  Primary cancer type                                                                                                          .4481
   Lung                                                                            3 (27.3%)             1 (9.1%)              
   Breast                                                                          0 (0.0%)              3 (27.3%)             
   Liver                                                                           1 (9.1%)              1 (9.1%)              
   Gastric                                                                         1 (9.1%)              2 (18.2%)             
   Esophagus                                                                       2 (18.2%)             0 (0.0%)              
   Prostate                                                                        1 (9.1%)              1 (9.1%)              
   Others                                                                          3 (27.3%)             3 (27.3%)             
  Working status (yes/no)^[†](#table-fn3-1534735420935643){ref-type="table-fn"}^   6 (54.5%)/5(45.5%)    3 (27.3%)/8 (72.7%)   .3870
  Insomnia period                                                                  14.0 \[6.0-28.0\]     27.0 \[4.0-36.0\]     .5602
  ECOG-PS (0/1)                                                                    7 (63.6%)/4 (36.4%)   7 (63.6%)/4 (36.4%)   .9999
  TNM stage                                                                                                                    .3579
   I                                                                               5 (45.5%)             1 (9.1%)              
   II                                                                              4 (36.4%)             6 (54.5%)             
   III                                                                             1 (9.1%)              1 (9.1%)              
   IV                                                                              1 (9.1%)              2 (18.2%)             
   NA                                                                              0 (0.0%)              1 (9.1%)              
  Usage of hypnotics (yes/no)                                                      2 (18.2%)/9 (81.8%)   3 (27.3%)/8 (72.7%)   .9999
  ISI score                                                                        18.0 \[15.0-22.0\]    18.0 \[14.0-22.0\]    .6034

Abbreviations: BMI, body mass index; ECOG-PS, Eastern Cooperative Oncology Group--Performance Status score; TNM, tumor nodes metastasis; ISI, Insomnia Severity Index.

*P* \< .05.

Wilcoxon rank sum test to analyze with non-parametric statistics.

The primary outcome is the difference of ISI between baseline and after the treatment. Although there is no significant difference of ISI between the 2 groups, both 2 interventions decreased the ISI score and the mean difference of treatment group is higher than that of the control group. Other variables including PSQI, ESS, and BFI were not significantly different between week 2 and week 4 within the group.

There is a significant difference between the treatment group and control group of SAS-K, with no difference in the baseline score ([Table 3](#table3-1534735420935643){ref-type="table"}). Other variables, including ISI, were not statistically different with the control group. Fitbit One data were not included in the result due to insufficient patient sleep data.

###### 

Outcome Difference After Treatment.

![](10.1177_1534735420935643-table3)

  Outcome                                                        Treatment group (N = 11)                                      Control group (N = 11)                                        *P* ^[a](#table-fn6-1534735420935643){ref-type="table-fn"}^
  -------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------
  ISI                                                                                                                                                                                        
   Baseline                                                      18.0 \[15.0 to 22.0\]                                         16.0 \[13.0 to 21.0\]                                         
   Week 2                                                        12.5 \[10.0 to 20.0\]                                         12.0 \[9.0 to 16.0\]                                          
    Difference                                                   −4.0 \[−7.0 to −2.0\]                                         −3.0 \[−6.0 to 0.0\]                                          .5507
    *P*^[b](#table-fn6-1534735420935643){ref-type="table-fn"}^   .0137                                                         .0430                                                         
   Week 4                                                        7.0 \[6.0 to 13.0\]                                           10.0 \[8.0 to 14.0\]                                          
    Difference                                                   −8.5 \[−12.0 to −5.0\]                                        −6.5 \[−10.0 to −3.0\]                                        .2266
    *P*^[b](#table-fn6-1534735420935643){ref-type="table-fn"}^   .0059[\*](#table-fn7-1534735420935643){ref-type="table-fn"}   .0059[\*](#table-fn7-1534735420935643){ref-type="table-fn"}   
  PSQI                                                                                                                                                                                       
   Baseline                                                      15.0 \[10.0 to 17.0\]                                         13.0 \[12.0 to 17.0\]                                         
   Week 4                                                        7.0 \[4.0 to 12.0\]                                           10.5 \[8.0 to 13.0\]                                          
    Difference                                                   −7.5 \[−9.0 to −5.0\]                                         −3.5 \[−5.0 to −2.0\]                                         .0782
    *P*^[b](#table-fn6-1534735420935643){ref-type="table-fn"}^   .0059[\*](#table-fn7-1534735420935643){ref-type="table-fn"}   .0039[\*](#table-fn7-1534735420935643){ref-type="table-fn"}   
  ESS                                                                                                                                                                                        
   Baseline                                                      10.0 \[5.0 to 16.0\]                                          6.0 \[3.0 to 13.0\]                                           
   Week 4                                                        5.0 \[3.0 to 7.0\]                                            4.0 \[3.0 to 5.0\]                                            
    Difference                                                   −4.0 \[−9.0 to 1.0\]                                          −1.0 \[−3.0 to 4.0\]                                          .4578
    *P*^[b](#table-fn6-1534735420935643){ref-type="table-fn"}^   .0879                                                         .7266                                                         
  SAS                                                                                                                                                                                        
   Baseline                                                      38.0 \[36.0 to 47.0\]                                         38.0 \[32.0 to 44.0\]                                         
   Week 4                                                        33.0 \[29.0 to 38.0\]                                         39.0 \[34.0 to 45.0\]                                         
    Difference                                                   −7.5 \[−9.0 to −4.0\]                                         2.0 \[−2.0 to 5.0\]                                           .0069[\*](#table-fn7-1534735420935643){ref-type="table-fn"}
    *P*^[b](#table-fn6-1534735420935643){ref-type="table-fn"}^   .0059[\*](#table-fn7-1534735420935643){ref-type="table-fn"}   .2070                                                         
  BFI                                                                                                                                                                                        
   Baseline                                                      4.8 \[3.0 to, 5.1\]                                           3.8 \[3.3 to 4.9\]                                            
   Week 4                                                        2.1 \[1.6 to 3.6\]                                            2.5 \[2.0 to 4.1\]                                            
    Difference                                                   −1.5 \[−2.3 to −1.2\]                                         −0.8 \[−1.3 to −0.1\]                                         .0796
    *P*^[b](#table-fn6-1534735420935643){ref-type="table-fn"}^   .0020[\*](#table-fn7-1534735420935643){ref-type="table-fn"}   .0840                                                         
  EQ-5D                                                                                                                                                                                      
   Baseline                                                      0.86 \[0.83 to 0.88\]                                         0.83 \[0.80 to 0.87\]                                         
   Week 4                                                        0.87 \[0.83 to 1.00\]                                         0.85 \[0.80 to 0.87\]                                         
    Difference                                                   0.00 \[−0.03 to 0.05\]                                        0.00 \[−0.13 to 0.01\]                                        .3893
    *P*^[b](#table-fn6-1534735420935643){ref-type="table-fn"}^   .6719                                                         .6875                                                         

Abbreviations: ISI, Insomnia Severity Index; PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Scale; SAS, Zung Self-Rating Anxiety Scale; BFI, Brief Fatigue Inventory; EQ-5D, Euroqol-5 Dimensions.

Wilcoxon rank sum test.

Wilcoxon signed rank test Median \[Q1-Q3\].

*P* \< .05.

Discussion {#section23-1534735420935643}
==========

The study is conducted to explore the feasibility of Cheonwangbosimdan in cancer patients with insomnia, known as traditional Korean herbal medicine effective for allaying insomnia. Cancer patients with insomnia were cared with Cheonwangbosimdan or CBT-I, primarily recommended treatment in insomnia patients.

Both groups presented reducing insomnia symptoms and enhancing the quality of cancer patients' life with significant difference between before and after treatment, although the result did not present the considerable difference of ISI and other insomnia outcomes between the 2 groups.

Cheonwangbosimdan consists of herbs such as *Ziziphus* seed, Thujae Semen, and *Polygala* root that mitigate anxiety symptoms and significantly lowered the anxiety score of insomnia patients in this trial. Components of Cheonwangbosimdan act for heart and anxiety symptoms are related to heart function deficiency^[@bibr56-1534735420935643]^ in traditional KM and Chinese medicine. Taiwan nationwide cohorts analyzed that Cheonwangbosimdan has been widely used for heart disease including ischemic heart diseases and chronic heart diseases.^[@bibr57-1534735420935643],[@bibr58-1534735420935643]^

Prevalence of insomnia in cancer is somewhat different according to the type of cancer. Most studies observed that breast cancer patients showed the highest prevalence of insomnia, with 38% to 50% of prevalence.^[@bibr59-1534735420935643],[@bibr60-1534735420935643]^ Prevalence of insomnia in lung (37%), gastrointestinal (32%), and gynecological (29% to 39%) cancer patients followed in sequence.^[@bibr61-1534735420935643]^ In Korea, a national database retrospective study found that lung cancer patients mostly suffered from insomnia (15.2%), non-Hodgkin lymphoma and bladder cancer followed, contrast to prior researches.^[@bibr62-1534735420935643]^ Although the prevalence of each cancer type is different and taking diverse measurement and subjects into consideration, the prevalence of insomnia in cancer patients is 3 times greater than the rate in the general population.

Despite the high prevalence, cancer-related insomnia is an overlooked disorder unlike psychological and physiological problems, as insomnia is regarded as a trivial side effect from both doctors and patients themselves. In the cancer patients' point of view, insomnia is a less important symptom to cancer itself.

In addition, insomnia patients who are comorbid with anxiety or depression assume that therapy for mental disorder is enough to vanish insomnia symptoms. Deficient experiences of oncology staffs dealing with insomnia also cause the neglect of insomnia symptoms.^[@bibr59-1534735420935643],[@bibr63-1534735420935643]^ Consequently, insomnia patients are reluctant to seek expert consultations.^[@bibr59-1534735420935643],[@bibr64-1534735420935643]^

Treating insomnia in cancer patients is important to precipitate their recovery. Sustained insomnia increases the risk of chronic diseases, including cancer incidence and cancer-related death, by augmenting inflammatory responses.^[@bibr65-1534735420935643][@bibr66-1534735420935643]-[@bibr67-1534735420935643]^ Sleep arousal activates NF-κB to release inflammatory and pro-inflammatory cytokines, which stimulates the onset of depression and fatigue.^[@bibr20-1534735420935643]^ The effects of insomnia on cancer risk is parallel to that of other chronic diseases. An increased risk of stroke was observed in both the primary insomnia cohort study^[@bibr68-1534735420935643]^ and European cancer cohort study with diabetes and myocardial infarction.^[@bibr69-1534735420935643]^

Association of certain cancer types and insomnia has been partly researched. In breast cancer, pre- and posttreatment sequences can affect the worsening of insomnia symptoms.^[@bibr70-1534735420935643]^ A Japanese cohort explained that hyperarousal augmented risk of prostate cancer.^[@bibr71-1534735420935643]^ Postmenopausal women cohort also presented that extremely short- or long-time sleep were associated with colorectal cancer.^[@bibr72-1534735420935643]^ Insomnia is one of the most common side effects of cancer treatment, with cancer-related fatigue.^[@bibr16-1534735420935643],[@bibr49-1534735420935643],[@bibr73-1534735420935643]^ Cancer-related fatigue consequently occurs after sleep disturbance, and these 2 factors are reciprocally affecting each other, as measurements of insomnia and fatigue are overlapped.^[@bibr74-1534735420935643],[@bibr75-1534735420935643]^

Insomnia presentations in cancer patients consists of primary insomnia, insomnia comorbid with pain or depression, and insomnia associated with cancer therapies and symptoms.^[@bibr76-1534735420935643]^ For cancer patients, the diagnosis of cancer can induce arousal due to anxiety, and the pain of chemotherapy stimulates wakefulness.^[@bibr77-1534735420935643]^

These intermingled factors for sleep disturbance in cancer patients require persistent and multidimensional sleep therapies. Hypnotic therapies can be hardly applied to chronic insomnia, with increasing dependence and tolerance over time requiring maintenance treatment^[@bibr78-1534735420935643]^ and longitudinally decreasing effectiveness.^[@bibr79-1534735420935643],[@bibr80-1534735420935643]^

Nonpharmacological studies such as sleep hygiene advices are also common.^[@bibr81-1534735420935643]^ CBT-I is more effective than medications,^[@bibr82-1534735420935643]^ and it is the first recommended treatment for insomnia according to national guidelines.^[@bibr83-1534735420935643]^ However, limited accessibility to experts and the relatively high costs of face-to-face--delivered CBT-I make patients indecisive to care with CBT-I.^[@bibr84-1534735420935643]^ Alternatively, nurse-led and internet CBT can be utilized with easy access to patients and higher adherence rate.^[@bibr85-1534735420935643],[@bibr86-1534735420935643]^

Insomnia Severity Index is an appropriate outcome to observe the insomnia status with PSQI for evaluating the effectiveness of CBT-I.^[@bibr18-1534735420935643],[@bibr31-1534735420935643]^ However, ISI is a more preferred scale for insomnia patients as PSQI can partially illustrate the longitudinal data because the survey only covers a 1-month period sleeping status, and ISI showed higher reliability with longitudinal data than PSQI.^[@bibr87-1534735420935643],[@bibr88-1534735420935643]^ Consequently, we decided ISI to be the primary outcome and PSQI an additional scale to examine cancer patients' sleep quality and difference in the time.

Complementary and alternative medicine can be utilized in insomnia with cancer. Movement therapies such as Yoga, reflexology, and Tai-Chi have been utilized and showed significant improvement.^[@bibr89-1534735420935643][@bibr90-1534735420935643][@bibr91-1534735420935643]-[@bibr92-1534735420935643]^ Traditional Chinese medicine also plays a role in caring for cancer-related insomnia. A systematic review that analyzed the effects of acupuncture on cancer-related insomnia concluded that the effect of acupuncture was similar to conventional drugs by measuring PSQI score.^[@bibr93-1534735420935643]^ Chinese herbal medicines relieving fatigue and insomnia showed the feasibility of utilization on cancer-related insomnia, as PSQI score was significantly lower than the control group.^[@bibr94-1534735420935643],[@bibr95-1534735420935643]^ Gamiguibi-tang, a traditional KM, also has been used to mitigate sleep disturbance represented efficacy and safety for cancer patients with insomnia.^[@bibr96-1534735420935643]^

In this study, insomnia in cancer patients was scrutinized with various scales, which measure physiological and psychological symptoms, commonly comorbid with insomnia, and enhanced the sensitivity of trial. With a sleep diary and insomnia survey questions, the insomnia status of cancer patients was cross-checked. Fitbit One data were not analyzed in this trial, because the activity tracker was out of stock while conducting the trial, and the sleep status data of patients were deficient to analyze and compare with sleep diary and other insomnia variables. Alternatively, another wearable activity tracker device, actigraphy, has been widely utilized to collect the sleep quality data with stable production,^[@bibr97-1534735420935643],[@bibr98-1534735420935643]^ and in the future studies, it can be also utilized given that the period of trial.

This trial has several limitations. First, this study could not associate the types and stages of cancer with insomnia severity, and small sample size. Second, the causality of insomnia and cancer could be hardly investigated in this study as the predisposing, precipitating, and perpetuating factors by patients' information were not fully collected. Despite these limitations, this study was the first clinical trial to observe the feasibility of Cheonwangbosimdan treatments on insomnia in cancer patients and support the ability to conduct large-scale trial in future.
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